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Title: Body composition, serum biomarkers of inflammation and quality of life in clinically stable
women with estrogen receptor positive (ER+) metastatic breast cancer (BC)

Abstract:
Limited data exist regarding body composition and associated patient-reported outcomes for
women with metastatic BC. Demographic, clinical, blood and questionnaire data were collected
to quantify body composition and explore associations with symptoms, inflammation and
quality of life (QOL) in 41 women with ER+ metastatic BC. Diagnostic/surveillance computed
tomography (CT) images including the third lumbar region (L3) were obtained to evaluate
skeletal muscle (SM) quantity and quality, and abdominal adipose tissue. Frequencies, medians
and interquartile ranges (IQR) are presented, stratified by sarcopenia and obesity (Body mass
index (BMI) ≥ 30.0 kg/m2). Overall, 34% (n=14/41), 49% (n=20/41) and 34% (n=14) of women
had sarcopenia, myosteatosis and obesity, respectively. Handgrip strength was compromised in
24% of participants (n=10/41). Women with sarcopenia had significantly lower body weight
(p=0.01), BMI (p=<0.001), and whole body SM (p<0.001), yet reported greater engagement in
leisure time exercises (p=0.05) vs. non-sarcopenic women. Women with obesity had
significantly higher levels of abdominal obesity (all values p <0.0001) and serum biomarkers of
inflammation (p values <0.06), yet lower QOL (p=0.02) vs. women without obesity. The
abPGSGA did not differentiate women with sarcopenia. Future interventions should test if
improvements in body composition are associated with better outcomes for this vulnerable,
emerging population.
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Introduction
Metastatic breast cancer (BC) occurs when malignant cancer cells spread beyond the
breast to regional (i.e., lymph nodes) or distant (i.e., bone, liver, brain) areas of the body. (1)
While 6% of women will initially present with metastatic BC, or de novo disease (2),
approximately 30% of women with early stage (I-III) BC will eventually experience disease
progression. Metastatic BC is presently incurable, but treatable by means of serial
administration of systemic therapies. The goal of treatment in the metastatic setting is to
simultaneously maximize disease response, minimize symptom burden and maintain the
highest quality of life (QOL). (1) Recent data from the American Cancer Society and the
Surveillance, Epidemiology, and End Results (SEER) Program report that only 22-26% of women
initially diagnosed with metastatic BC survive 5 years, with most succumbing to their disease
within 2-3 years of metastatic diagnosis. (2, 3) However, it is unclear if these data reflect the
survival benefits observed from targeted therapies, including cyclin dependent kinase (CDK) 4
and 6 inhibitors or human epidermal growth factor receptor-2 (HER-2). (4, 5) Statistical models
from Mariotto et al (6) show that the number of women living with metastatic BC has increased
2-3 fold over the last two decades, especially among those who are younger and have de novo
disease. Thus, women with metastatic BC are a growing sector of the cancer survivorship
population and we have limited information regarding issues unique to their survivorship.
Approximately 40-60% of patients present with overweight or obesity at the time of their
cancer diagnosis. (7) Unlike other cancer therapies, BC treatment, itself, is associated with weight
gain, often resulting in increased levels of adipose tissue with or without the loss of lean mass
(LM). (8) This phenomenon is well-documented in women undergoing treatment for early stage
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BC (I-III), (9-14) but not well investigated in women with late stage disease. Due to the routine
use of computed tomography (CT) imaging in the metastatic setting, obtaining precise estimates
of body composition in this population is achievable. (15, 16) However, prior studies have only
examined body composition at initial metastatic BC diagnosis and were restricted to outcomes
available in the electronic medical record (EMR). (15, 16) Previously, the lifestyle habits of 25
women with metastatic BC receiving a variety of cancer therapies at different stages of their
disease trajectory were investigated. (17) Forty-four percent (n=11/25) voiced concerns
regarding unfavorable treatment-related weight gain, as well as infrequent physical activity and
dietary intake patterns high in fat and low in fiber. Only surrogate measures of body composition
were reported. Building upon this, for the current study we used a convenience sample of
women with clinically stable estrogen receptor positive (ER+) metastatic BC to examine the
prevalence of compromised SM, specifically sarcopenia and myosteatosis, as well as abdominal
adiposity, lifestyle factors, quality of life (QOL) and serum biomarkers of inflammation. We
hypothesized that women who reported higher levels of fatigue or lower QOL would exhibit
compromises in SM.
Materials and Methods
This cross-sectional study recruited eligible women from a university-affiliated cancer
center (February, 2015 - October, 2017) as part of a Phase 1 vitamin D supplementation trial
(NCT02186015). Female participants were required to be: 1) >18 years of age, 2) undergoing
treatment for histologically confirmed estrogen receptor positive (ER+) metastatic BC, 3) at a
performance status of 0-2(18) and 4) deemed clinically stable by their medical oncologist (i.e.,
no unexplained weight loss, no changes in anti-neoplastic agents within the last 30 days, no
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new clinical or radiologic evidence of disease progression, uncontrolled pain or < 6 months of
life anticipated). Informed consent was obtained at a routine clinic visit and anthropometric
and questionnaire data were obtained at a separate time. Additional eligibility for the present
study included: 1) completion of the study questionnaires, and 2) a chest, abdominal, pelvis CT
study including the L3 region completed as part of the standard of care. This study was
approved the Institutional Review Board of Loyola University Chicago.
Demographic and medical information: Demographic (age, race/ethnicity, living situation
employment status) and medical information (breast cancer surgery, previous and current cancer
treatments, metastatic sites) were gathered from the electronic medical record (EMR) and/or
the participant, as appropriate.
Nutrition assessment: During a research visit, height was measured to the nearest 0.1 cm using
a clinic stadiometer (Digital Physician Scale Health O Meter 500KL; McCook, IL) and weight was
measured to the nearest 0.1 kg using a portable digital scale (Tanita BF-350; Arlington Heights,
IL). Participants wore light clothes and were measured without shoes. If two measurements
were more than 0.5 cm or 0.2 kg apart for height and weight, respectively, a third
measurement was taken. The two closest measures of height and weight were used to calculate
BMI (kg/m2) and to classify obesity status (defined as BMI ≥ 30.0 kg/m2). (19) Participants
completed the abridged Patient Generated Subjective Global Assessment (aPG-SGA); a
validated 4 component nutrition assessment tool that assigns numeric values related to weight
patterns, food intake, symptoms, and activities and function. Unlike the global Subjective
Global Assessment (SGA)(20), the aPG-SGA is self-administered and does not include a physical
examination. Higher scores are indicative of greater symptom burden and scores ≥ 6 points are
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associated with malnutrition. (21) To crudely assess dietary intake, participants completed a
validated on-line fruit, vegetable and fiber screener.(22) This 10 item dietary screener takes ~5
minutes to complete and ranks individuals with regard to their usual intake of fruits and
vegetables, providing point estimates of total fruit/vegetable servings and dietary fiber. (23)
Output from dietary screener was recorded in hard-copy format. All nutrition assessments were
completed prior to CT imaging retrieval and analyses.
Body composition: Generally, imaging studies are completed for surveillance purposes every 36 months for women with ER+ metastatic breast cancer. Imaging is performed more often in
women with increased symptoms and suspected disease activity, and less often in women with
decreased symptoms and disease stability. The CT image performed for clinical purposes and
closest to the participant’s baseline study visit was utilized for these analyses. Archived images
of the third lumbar (L3) region were identified and anonymized by the Radiology staff. An
investigator certified in body composition assessment and blind to outcomes assessment
completed the analyses using Slice-O-Matic software (v.4.3; Tomovision, Montreal, Quebec,
Canada).
SM quantity: Estimates of whole-body skeletal muscle (kg) were calculated from the regression
equation of Mourtzakis et al (24) as follows: 0.30 X [skeletal muscle area at L3 region using CT
(cm2)] + 6.06 (r=0.94; p<0.001). These values were then normalized for stature, height in meters
squared (kg/m2). To derive skeletal muscle index (SMI), L3 muscle area measures were
normalized by height in meters squared [(SMI) cm2/m2]. To assess the prevalence of CTdetected sarcopenia, we applied the lumbar SMI cut-point for females of < 41.0 proposed by
Martin et al established in larger oncologic patient population.(7) Sarcopenic obesity for
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females was defined as a lumbar SMI <41.0 cm2/m2 and a BMI > 30 kg/m2. (The term sarcopenia
is used henceforth synonymously with CT-detected sarcopenia.)
SM quality: Skeletal muscle ranges between -29 to +150 Hounsfield units (HU; the CT unit of
measure of radiodensity). However, in individuals who are obese (25) or have type 2 diabetes
mellitus (26), SM attenuation values are lower symbolizing fatty infiltration of the muscle and a
reduced oxidative capacity. (27) Myosteatosis was defined as <41 HU for BMI <24.9 kg/m2 and
<33 HU for BMI ≥25.0 kg/m2, using the cut-points of Martin et al. (7)
Adipose tissue: Abdominal obesity, specifically visceral adipose tissue (VAT) and subcutaneous
adipose tissue (SAT), are associated with elevated serum biomarkers of inflammation in healthy
populations.(28) As part of the CT body composition analyses, measurements of VAT and SAT
were quantified. Adipose tissues range according to Hounsfield Unit (HU) thresholds, where
−150 to −50 are used for VAT and −190 to −30 are used for SAT. Total adipose tissue (TAT) was
calculated as sum of the areas of SAT + VAT.
Quality of life (QOL): Women completed the Functional Assessment of Cancer Therapy-Breast
(FACT-B) (29) and the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACTES). (30) These tools measure multidimensional QOL, including four sub-scale domains (physical
well-being, social/family well-being, emotional well-being, and functional well-being), in
addition to concerns regarding BC and endocrine symptoms. The FACT-B includes ten additional
questions specific to BC, while the FACT-ES contains 18 additional items related to endocrine
symptoms; the latter being highly relevant for women with ER+ disease. Maximum scores for
these instruments are 144 and 220, respectively, with higher composite scores indicating better
QOL.
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Pain: The Brief Pain Inventory-Short Form (BPI) was specifically designed to assess pain in
cancer patients. It includes four items measuring the severity of pain in the last 24 hours, plus
seven additional items measuring the extent to which pain interferes with life activities. Higher
overall scores indicate greater pain experiences. (31)
Fatigue: The Piper Fatigue Scale (PFS) is a validated tool, composed of 22 numerically scaled "0"
to "10" items. It measures four dimensions of subjective fatigue, including: behavioral/severity
(6 items); affective meaning (5 items); sensory (5 items); and cognitive/mood (6 items.) Higher
overall scores are indicative of greater fatigue. (32)
Physical functioning: Women completed the Godin Exercise Leisure-time Questionnaire; a 4item tool that demonstrates reliability coefficients of 0.8 with V02 measures (33) and allows for
the quick quantification of time spent engaged in strenuous, moderate or light activities over a
typical 7-day period. In addition, handgrip strength (kg) was measured with a Jamar Plus
handgrip dynamometer following standard study procedures. (34) Measures were obtained in
duplicate for each participant’s non-dominant and dominant hands during their study
appointment. Scores of the dominant hand were averaged and the cut-point of < 20 kg was
used to define compromised functioning. (35)
Serum biomarkers of inflammation: Blood biospecimens were acquired prior to routine clinic
appointments, processed immediately and stored at -80°C until the time of analyses. ELISA
assay kits were purchased from R&D Systems (Minneapolis, MN) to profile concentrations of
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and from Aniara Diagnostica
(Westchester, OH) to quantify C-reactive protein (CRP). All samples were run in duplicate with
controls.
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Statistical Analyses: Descriptive statistics were conducted to examine differences in baseline
demographics, clinical characteristics, symptom reports and QOL stratified by sarcopenia
and/or obesity status using BMI (≥ 30.0 kg/m2). Sensitivity analyses were completed to assess
the prevalence of sarcopenia for variable windows of time (e.g., 30, 60 and >60 days) between
questionnaire completion and CT imaging. Patient characteristics are presented as medians,
interquartile ranges, or counts and percentages. Statistical differences between groups were
assessed with Wilcoxon rank-sum tests or Fisher’s exact test for continuous and nominal
variables, respectively. Analyses were performed with SAS version 9.4 (Cary, NC) and based on
the exploratory nature of this study, a p value of <0.10 was used to denote trends and
statistical significance.
Results:
A total of 43 women were enrolled in the parent trial (NCT02186015). Of these, 1 woman
withdrew completely and 1 participant did not have any available CT images, leaving 41
participants with evaluable data for the present analyses. The average participant was 59.6 (±
11.9) years of age and 26.3 (± 33.8) months since her metastatic BC diagnosis. The majority of
women were non-Hispanic white (73%), had metastases to the bone, liver and/or lung, and
were employed full or part-time (44%). As seen in Table 1, women who were classified with CTdetected sarcopenia were significantly older (p=0.03), disproportionately non-Hispanic white
(p=0.02) and receiving less targeted therapies compared to women who were non-sarcopenic
(p=0.02).
Our sensitivity analyses demonstrated that the prevalence of sarcopenia was 22.7%
(n=5/22), 25.0% (n=2/8) and 63.6% (n=7/11) for women who completed questionnaires within
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30, 60 or >60 days (61-159 days) of CT imaging, respectively. To address the potential
differences for women imaged less frequently, we analyzed our patient reported outcomes of
interest for those restricted to 60 days between questionnaire completion and CT imaging.
Similar to the larger group (n=41), there were no significant differences between nonsarcopenic vs. sarcopenic women with regard to abPGSGA total scores (4.2 vs. 2.1, p=0.16),
FACT-Breast total score (100 vs. 112, p=0.21), FACT-Endocrine Symptoms total score (157 vs.
181. P=0.07), total fatigue (4.5 vs. 2.4, p=0.10) and daily pain (3.7 vs. 2.6, p=0.29).
Table 2 depicts the differences in body composition, lifestyle factors, QOL, symptoms
and serum biomarkers of inflammation stratified by sarcopenia. Overall, 34% (n=14/41) of
participants were sarcopenic and 49% (n=20/41) of all women exhibited myosteatosis; 22%
(n=9) exhibited both of these conditions. Women with sarcopenia had significantly lower body
weight (p=0.01), BMI (p=<0.001), whole body SM (p<0.001) and abdominal adipose tissue (p
values <0.003), yet they reported significantly greater engagement in leisure time exercise
activity (p=0.05), when compared to those without sarcopenia. Dominant handgrip strength
was compromised in 24% of women (n=10/41), which was not different between groups and 4
women (10%) exhibited both, reduced handgrip strength and sarcopenia. Findings from the
abPG-SGA showed that nutrition impact symptoms were more frequently endorsed among
those classified as non-sarcopenic vs. sarcopenic (p=0.08, respectively.) Fatigue and pain were
reported by 100% (n=41) and 85% (36) of all participants, respectively. No differences in fruit,
vegetable, fiber intake, fatigue or pain were detected between groups. In general, women with
sarcopenia had higher total scores on both the FACT-Breast and the FACT-Endocrine Symptoms.
When the subscales of these instruments were analyzed, non-sarcopenic women reported
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lower endocrine symptoms scores compared to sarcopenic women, respectively (p=0.01). (Data
not shown) Serum biomarkers of inflammation showed trends toward higher CRP in nonsarcopenic vs. sarcopenia women (p=0.09).
Table 3 depicts the differences in body composition, lifestyle factors, QOL, symptoms
and serum biomarkers of inflammation stratified by obesity status using BMI. Overall, 34%
(n=14/41) were classified as obese and myosteatosis occurred nearly equally among the
women with normal/overweight vs. with obesity. Women with obesity had significantly greater
body weight (p=<0.0001), whole body SM (p<0.01), reduced SMHU (p=0.02) and abdominal
obesity (all p values <0.0001), and reported less time engaged in leisure time exercise activity
(p=0.07) compared to women without obesity. Women with obesity also had significantly lower
QOL scores for breast (p=0.07) and endocrine symptoms (p=0.02), as well as daily pain (p=0.09)
when compared to women without obesity. When the subscales of the QOL instruments were
analyzed, women with obesity tended to reported lower physical and emotional well-being vs.
women with normal/overweight. (Data not shown) Significantly higher levels of CRP (p=0.06)
and TNF-α (p=0.03) were observed for women with obesity vs. without obesity. No differences
in fruit, vegetable, fiber intake or handgrip strength was detected between obesity groups.
Discussion:
This exploratory study found that sarcopenia was prevalent in one of three women with
ER+ metastatic BC. Our findings are consistent with Prado et al (15), but lower than the 58%
prevalence reported by Shachar et al. (16) Our study is different, however, in that we only
recruited women with ER+ metastatic BC. Additionally, our participants were at various phases
of their disease course and we explored potential associations with patient-reported outcomes
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in ‘real’ time. We believe our findings may underestimate the occurrence of sarcopenia in this
patient population since women were required to be clinically stable in order to participate in
the parent investigation. Compared to a broader group of women with metastatic BC receiving
more varied treatment regimens or undergoing more frequent CT imaging due to disease
activity, our participants may be inherently “healthier.” Interestingly when we compare our
QOL findings to a larger normative group of women with metastatic BC (n=98) (30), our women
with sarcopenia have very similar mean scores for physical (22 vs. 22) and functional well-being
(19 vs. 19), as well as total scores for the FACT-B (115 vs. 109) and FACT-ES (172 vs. 174),
respectively. Although these findings are in contrast to our proposed hypotheses, women in our
trial do reflect the needs and characteristics of those whom we would recruit for a lifestyle
intervention targeting improvements in symptom management. Thus, these results make an
important contribution to the limited literature on this growing population of survivors.
Previous studies have shown that sarcopenia adversely impacts chemotherapy toxicity
and/or overall survival in pancreatic (36), renal (37, 38), respiratory, and gastrointestinal
cancers. (39) Two studies have specifically examined oncology-related outcomes in women with
metastatic BC. Prado et al investigated the clinical implications of SM in 55 women with ER+
and ER- metastatic BC starting capecitabine chemotherapy treatment. Women who were
sarcopenic (SM < 38.5 cm2/m2) at treatment initiation (n=14/55) exhibited significant
chemotherapy toxicities and shorter time to tumor progression compared to those with higher
levels of SM. (15) Further, Shachar et al investigated the associations between sarcopenia and
conventional oncology outcomes in 40 women with both ER+ and ER- metastatic BC receiving
first line taxane-based chemotherapy. (16) These authors reported significantly higher toxicity-
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related hospitalizations and more severe adverse events (i.e., grade 3–4 toxicities,
hospitalizations, dose reductions, or dose delay) in women with sarcopenia (n=23) vs. those
without (n=17). Additionally, these investigators reported that myosteotosis was also
associated with grade 3-4 toxicity, the need for hospitalization and time to treatment failure
(for progression or toxicity) (all p values < 0.04). Because chemotherapy dosing relies on body
surface area using current height and weight, these calculations presume a constant proportion
of adipose to lean tissue. In the setting of sarcopenia, these body composition assumptions are
violated. As suggested by Prado et al, decreased levels of SM reflect a lower volume of
chemotherapy drug distribution, resulting in greater toxicity reports, dose delays or treatment
cessation. (39) While this concept is beyond the reach of the current study, it is clear that SM is
an important prognostic tissue biomarker for women with metastatic BC. As discussed by the
Cruz-Jentoft et al on behalf of the International Sarcopenia Initiative (40), identifying effective
ways to improve SM is difficult; however, such interventions could have profound implications
on treatment tolerance and survival for this clinical population.
While the primary focus of this study was SM, our stratification by obesity highlighted
some intriguing findings. In particular, the concept that women classified with obesity
experience a tendency toward greater symptomology and lower multidimensional QOL when
compared to women with normal weight or overweight. BMI is considered a surrogate marker
of body composition, specifically adiposity (41, 42) and many studies have demonstrated the
high variability of SM in different oncology populations, independent of BMI categories. (7, 39,
43-45) Considering that the majority of our women with sarcopenia fell within the normal BMI
range (18.5-24.9 kg/m2) and the low prevalence of sarcopenic obesity (n=1), leaves us to
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speculate on other potential mechanisms besides sarcopenia. Because women with obesity
were found to have significantly lower SM quality (using SMHU; p=0.02), we analyzed fatigue,
pain and multidimensional QOL stratified by myosteatosis. No relationships were revealed.
Previous studies have demonstrated that persistent elevations in circulating pro-inflammatory
cytokines [e.g., IL-6, TNF-α] are observed in early stage BC survivors for years after treatment
and are associated with adverse symptomology and reduced QOL.(46, 47) Based on the
significantly higher levels of CRP, TNF-α, VAT, SAT and TAT in our women classified with obesity
vs. those without, the potential role of inflammation merits further exploration.
An important, yet subtle finding of this study is the fact that sarcopenia was present in
women considered at ‘low’ nutrition risk, when using the abPG-SGA as a nutrition screening
tool. In a previous study by Gabrielson et al (21), these authors reported that scores ≥ 6 on the
abPG-SGA were highly correlated with oncology patients classified as malnourished when the
full versions of the PG-SGA (97% sensitivity, 86% specificity, AUC = 0.967) and the Malnutrition
Screening Tool (81% sensitivity, 72% specificity, AUC = 0.823) were administered. Several other
investigators have also demonstrated that inabilities of other common nutrition screening
tools, including the Malnutrition Universal Screening Tool (MUST), Malnutrition Screening Tool
(MST), and the Nutritional Risk Index (NRI), to detect compromised body composition in a
heterogeneous group of oncology populations. (48-50) In direct contrast to our study, these
investigations included patients with cancer cachexia; a population deemed ineligible for our
larger study. Despite these differences and the fact that our study specifically applied the abPGSGA, a nutrition screen tool designed for the out-patient oncology population, this growing
body of work highlights the limitations of these widely implemented nutrition screening tools. A
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particular challenge for oncology practitioners is the inability to detect SM depletion among
those with overweight or obesity. Unlike cancer cachexia, where there are more overt signs of
wasting (i.e., subjective complaints of unintentional weight loss, global adipose tissue loss,
muscle wasting, etc.), sarcopenia is an occult condition not detectable upon physical
examination or supported with questions taken during a routine history. In patients with
overweight or obesity, mild changes in weight go unnoticed or are so subtle, they are missed
even by experienced practitioners. In addition, the scale may show no net change as SM
deteriorates and adipose tissue increases. Thus, it is becoming increasingly paramount to try to
identify methods to incorporate imaging into our modern nutrition assessment techniques, as
reiterated by these study results.
This study is not without limitations and a few points merit highlighting. First, we used
CT images that were closest to the time of our initial study assessment. Previous investigators
have used a 30-45 day window to correlate physical measures (e.g., body weight, BMI) with CT
imaging to examine outcomes. (7, 39) However, we reasoned that a larger window for
assessment was allowable because: 1) anthropometric measures and symptom assessments
were obtained in ‘real time’ vs. retrospectively calculated from the EMR, and 2) our eligibility
criteria eliminated women experiencing unintentional weight loss, cachectic in appearance and
with new clinical or radiologic evidence of disease progression. While this provided a unique
opportunity to explore body composition in this patient population, the larger window of time
between questionnaire completion and CT imaging (range 0-159 days) may have unknowingly
impeded our abilities to link important patient-reported outcomes with SM. Second, we only
had 41 women included in these analyses and we may be statistically underpowered to detect
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differences in outcomes between groups. We also examined CT-detected sarcopenia, as it was
not practical to explore outcomes for the 4 women who met the diagnostic criterion for
sarcopenia, which includes reduced SM and compromised muscle strength. (35) Studies that
are adequately powered are warranted to better explore the potential relationships between
patient-reported outcomes and SM. Third, a fruit and vegetable screener was completed to
evaluate dietary intake due to its ease and low burden relative to other study activities;
however, more detailed dietary assessment methodologies (e.g., food records, food frequency
questionniares) are needed to support a comprehensive nutrition assessment. Fourth, handgrip
strength was used to obtain a simple, quantifiable measure of physical functioning. Likely more
in-depth assessments of overall physical conditioning and functioning are needed to establish
associations with lean mass and general fitness, similar to Jones et al (51) or Yee at al (52) in
women with metastatic BC. Finally, this is a cross-sectional study and the data can only be used
to for hypothesis generation; no cause and effect relationships can be established
Conclusions:
The rising incidence of metastatic BC at initial diagnosis combined with expanding
treatment options have resulted in a steadily growing population of women living with this
disease. (4, 5, 53) Our study continues to support the wide-spread prevalence of CT-detected
sarcopenia and myosteatosis, now documenting their occurrence in an exclusive population of
ER+ women. Our findings also reiterate the importance and potentially intertwined relationship
of obesity, inflammation and QOL. Future interventions supported by multidisciplinary team
efforts are needed to improve the body composition of women with ER+ metastatic BC in the
hopes of potentially improving a broad array of relevant outcomes. Additionally, studies
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gathering data at more than one time point would provide important opportunities to observe
the trajectories of change during the time course of survivorship.
Acknowledgements: We acknowledge the efforts of Dr. Ellen Gaynor for her assistance with
this study.
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